Press releases

Clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

"We remain focused on executing our strategy to drive this organization back to revenue growth,” said CEO Hank Kucheman.

REPRISE II study results expected to support CE Mark and other regulatory filings.

Victory™ guidewires are designed to facilitate crossing of resistant lesions.

Pending addition of next generation mapping and navigation system would expand company portfolio into complex electrophysiology procedures.

Learn how to tune in for the webcast or the replay.

Disorders affect nearly 30 million American women; new research shows high prevalence of patients not understanding their treatment options.

S-ICD System is the world's first and only commercially available completely subcutaneous implantable defibrillator.

S-ICD System is world's first and only commercially available completely subcutaneous implantable defibrillator.

First and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.